Criteria for Presumptive Diagnosis of IgD Multiple Myeloma
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
Human Kappa and Lambda Free Light Chain Control - Sekisui Diagnostics
Serum reagent kit - FLC - Sebia - clinical / laboratory / blood sample
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia
Kappa/lambda serum FLC ratio in patients with IgG4-RD. Comparison of... | Download Scientific Diagram
SEBIA FLC - serum free light chain quantification
Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research
Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument - ScienceDirect
Hani Rustom posted on LinkedIn
Comparison of the distribution of kappa and lambda free light chains... | Download Scientific Diagram
A universal reference interval for serum immunoglobulins free light chains may be outdated
Serum reagent kit - FLC - Sebia - clinical / laboratory / blood sample
Table 3 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
Method comparison of four clinically available assays for serum free light chain analysis
Examples of abnormal kappa/lambda free light chain (κ/λ FLC) ratios in... | Download Table
Discrepancy in serum free light chain analysis compared with serum... | Download Scientific Diagram
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
Sebia And Abingdon Health Sign Exclusive Global Distribution Agreement | Medical Product Outsourcing
IJMS | Free Full-Text | Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal
November 18, 2022 Sebia, Inc. Karen Anderson Director of Regulatory 1705 Corporate Drive, Suite 400 Norcross, Georgia 30093 Re:
